Cero Therapeutics sees $383,369 in inventory gross sales by YK Bioventures

BURLINGAME, CA—Cero Therapeutics Holdings, Inc. (NASDAQ:CERO), a micro-cap biotech firm with a market capitalization of $16.44 million, lately skilled important inventory gross sales by YK Bioventures Alternatives Fund I, L.P., a significant shareholder. In accordance with a latest SEC submitting, the fund offered a complete of three,659,364 shares over three days, from December 6 to December 10, 2024, producing roughly $383,369.

The gross sales have been executed at costs starting from $0.09 to $0.12 per share, with the inventory now buying and selling close to its 52-week low of $0.06, down 99% year-to-date. After these transactions, YK Bioventures Alternatives Fund I, L.P. retains possession of 18,962,419 shares of Cero Therapeutics. InvestingPro evaluation reveals a number of warning indicators, together with important value volatility and weak monetary metrics.

The shares are held immediately by YK Bioventures Alternatives Fund I, L.P., with YK Bioventures Alternatives GP I, LLC appearing as the overall associate. Mitchell W. Kossar and Gary Ok. Yeung, managing companions, are famous to have shared voting and funding energy over the shares. Nonetheless, they disclaim useful possession besides to the extent of their pecuniary curiosity.

These transactions replicate ongoing exercise by main shareholders in Cero Therapeutics, an organization engaged within the life sciences sector.

In different latest information, CERo Therapeutics has obtained FDA approval to start Section 1 scientific trials for its main drug candidate, CER-1236, focusing on acute myelogenous leukemia (AML). The corporate has additionally confronted potential delisting from NASDAQ resulting from non-compliance with the change’s minimal bid value requirement and the Market Worth of Listed Securities requirement, however has requested a listening to to enchantment this determination. Amid these challenges, CERo Therapeutics has seen important adjustments in its administration group, with the appointments of Al Kucharchuk as Chief Monetary Officer and Kristen Pierce as Chief Growth Officer, and the addition of Shami Patel to the board of administrators. Regardless of a scientific maintain by the FDA on CER-1236, the corporate has accomplished pre-IND manufacturing actions for the drug and plans to start scientific trials in 2025. The corporate additionally reported a money stability of $3.2 million as of September 2024, and secured $1.25 million from present buyers. These latest developments spotlight CERo Therapeutics’ ongoing efforts to beat present challenges and advance its strategic goals.

This text was generated with the help of AI and reviewed by an editor. For extra info see our T&C.